ClinicalTrials.gg
RecruitingNCT05762328ADAPTUpdated Jan 11, 2024

Duration of Antibiotic Treatment in Community-acquired Pneumonia

An interventional study of Reminders to the assistant clinicians of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment community-acquired pneumonia in Community-acquired Pneumonia, sponsored by Instituto de Investigacion Sanitaria La Fe. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-01-11.

Sponsored by Instituto de Investigacion Sanitaria La Fe · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Community-Acquired Pneumonia with a site in Spain — 5 open to participants now, 6 under way, 3 of them phase 3. Community-Acquired Pneumonia · Spain.

Planned enrollment
3rd of 23
2,000 · median 314
Started
2024
with 1 other
No phase
5 of 32
1 open now
Registered
29th of 32
by date

Among the 32 studies in Community-Acquired Pneumonia with a site in Spain, this one is the 3rd largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 with no phase, and was the 29th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

5 of the 32 studies in Community-Acquired Pneumonia with a site in Spain are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Community-Acquired Pneumonia with a site in Spain, or all of them as a file.
02

Study summary

International and national clinical guidelines recommend short antibiotic regimens in patients with non-severe community-acquired pneumonia (CAP) who have reached clinical stability. However, adherence to these recommendations remains unclear. The goals of this quasi-experimental trial are: 1) to assess adherence to clinical guidelines in relation to the duration of antibiotic treatment in patients hospitalized for non-severe CAP who have reached clinical stability; 2) increase adherence to clinical guidelines and reduce the use of antibiotics in patients hospitalized for non-severe CAP who have achieved clinical stability after at least 5 days of antibiotic treatment.

To this end, a multicenter prospective study will be carried out over 2 years and divided into 2 phases: i) during the first year (observational phase), patients with CAP hospitalized in the participating centers will be recorded to assess objective 1; ii) to achieve objective 2, at the beginning of the second year (quasi-experimental trial) the centers will be randomized into 2 groups of hospitals, one of them a control group and the other an intervention group. The intervention will consist in automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability.

03

Conditions studied

  • Community-acquired Pneumonia

Keywords

  • pneumonia
  • antibiotic treatment
  • duration
  • clinical stability
  • adherence
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients >18 years hospitalized for community-acquired pneumonia with a new infiltrate on chest X-ray and/or computerized tomography.
  • At least one compatible sign or symptom (fever, cough, expectoration, dyspnea, chest pain or crackles on auscultation)
  • Correctly treated with ≥ 3 days of antibiotic

Exclusion criteria

Exclusion Criteria:

  • Intensive care unit admission during the first 5 days since hospital admission
  • Abscess or necrotizing pneumonia
  • Empyema or pleural effusion requiring drainage tube
  • Bronchiectasis
  • Cystic fibrosis
  • Active tuberculosis
  • Postobstructive pneumonia
  • Suspected bronchial aspiration
  • SARS-CoV-2 infection
  • (congenital immunodeficiencies, infection, solid organ transplantation, functional or anatomical asplenia, immunosuppressive treatment, active solid or haematological neoplasia [active treatment in the last 12 months], etc.)
  • Hospital acquired pneumonia
  • Concomitant extrapulmonary infection that requires antibiotic treatment for more than 5 days (eg myocarditis)
  • Confirmed diagnosis alternative to pneumonia (eg, lung cancer)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
2,000 participants (estimated)

Study arms

  • No intervention
    Standard of care

    Patients allocated in hospitals randomized to non-interventional arm. Observational analysis of patients treated by clinicians with standard of care.

  • Other
    Interventional

    Patients allocated in hospitals randomized to interventional arm. Intervention: automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability

    Behavioral: Reminders to the assistant clinicians of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment community-acquired pneumonia

Interventions

  • BehavioralReminders to the assistant clinicians of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment community-acquired pneumonia

    Automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability

    Also known as: Reminders to the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability

06

What researchers measure

Primary outcomes

  1. Duration of antibiotic treatment

    Total duration in days of antibiotic treatment (including the days of outpatient antibiotic prescribed at discharge).

    Time frame: 90 days

Secondary outcomes

  1. Duration of antibiotic treatment after reaching clinical stability

    Duration in days of antibiotic treatment after reaching clinical stability

    Time frame: 90 days

  2. Patients treated with an adequate duration of 5±1 days

    Percentage of patients treated with an adequate duration of 5±1 days

    Time frame: 90 days

  3. Patients admitted to the ICU after the 5th day

    Percentage of patients admitted to the ICU after the 5th day of admission

    Time frame: 90 days

  4. Mortality

    Percentage of patients who died during the study

    Time frame: 90 days

  5. Readmission

    Percentage of patients who are readmitted after hospital discharge

    Time frame: 90 days

  6. Reintroduction of antibiotic treatment

    Percentage of patients with reintroduction of antibiotic treatment

    Time frame: 90 days

  7. Length of hospital stay

    Length of hospital stay in days

    Time frame: 90 days

  8. Adverse events related to antibiotic treatment

    Percentage of patients with adverse events related to antibiotic treatment

    Time frame: 90 days

Other outcomes

  1. Factors related to excess of antibiotic treatment

    Factors o variables related to excess of antibiotic treatment

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Jun 2025, 17 months later.

Of 42 non-industry interventional studies with no phase under Community-Acquired Pneumonia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 38. This study's planned 17 months is below that.

Counting every sponsor, half of 43 studies reached it within 24 months; a quarter within 14 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2023
First posted
Mar 9, 2023
StartEst.
Jan 2024
Primary completionEst.
Jun 2025
CompletionEst.
Aug 2025
Last update
Jan 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05762328
Lead sponsor
Instituto de Investigacion Sanitaria La Fe
Collaborators
Instituto de Salud Carlos III, Sociedad Española de Neumología y Cirugía Torácica, Sociedad Valenciana de Neumología
Responsible party
Raúl Méndez, MD PhD (Dr., Instituto de Investigacion Sanitaria La Fe) — Principal investigator
First posted
Mar 9, 2023
Start date
Jan 2024 (estimated)
Primary completion
Jun 2025 (estimated)
Completion
Aug 2025 (estimated)
Last update
Jan 11, 2024

Study contacts

Raúl Méndez, MD, PhD
Contact
rmendezalcoy@gmail.com
+34 961244000 ext. 485629
Raúl Méndez, MD, PhD
principal investigator · Instituto de Investigación Sanitaria La Fe

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion